On the basis of multiple studies reporting that percutaneous transluminal coronary angioplasty (PTCA) is both feasible and relatively safe in patients with multivessel coronary disease,'-5 this form of therapy has now been advocated as an alternate form of revascularization to coronary artery bypass surgery, which has been the standard treatment for many such patients. 6 Initial reports of follow-up after PTCA have shown primary procedural success in 83-93%, relief from angina pectoris in 81-92%, need for late bypass surgery in 3-12%, and late mortality in 0-5% of patients after 7-37 months.1-5,7-10 However, careful subgroup analysis to establish criteria by which to estimate the likelihood of long-term success 
Angioplasty Procedure
The techniques of coronary angioplasty used and initial in-hospital follow-up have been described.'
Angiographic Analysis
One of two experienced angiographers at the angiographic core laboratory without knowledge of clinical outcome reviewed the diagnostic and procedural angiograms to determine suitability for study entry and code for 18 stenosis and 13 patient variables. All quantitative measurements were made using hand-held calipers, and percent diameter stenosis was obtained from the mean of measurements in orthogonal projections at end diastole, when possible. Thirty patients were excluded from the study because of nonvisualization of a contralateral coronary artery (n=17), presence of one-vessel disease (n=7), inadequate stenosis visualization (n=4), and an angioplasty not performed during the study period (n =2). Additional patients were then requested until each institution's quota was met.
The angiographic definitions used by the Multivessel Angioplasty Prognosis Study (MAPS) Group and morphological characteristics of the stenoses,1" their jeopardized territories, and the presumed viability of the myocardium subserved. The American College of Cardiology/American Heart Association (ACC/AHA) stenosis classification (see Table 1 collaterals had a stenosis that was dilated. The jeopardized territory equaled the sum of branches distal to the stenosis dilated divided by the sum of all branches of the coronary tree (see Figure 1 ). Primary target stenosis rsk-territory-contractility score.
The primary target stenosis risk-territory-contractility score was the product of the modified ACC/AHA score of the primary target stenosis multiplied by the jeopardized territory multiplied by segnental contractility. Sum of all stenosis risk-territory-contractility scores: This score was defined as the sum of all individual stenoses' risk-territory-contractile scores.
Clinical variables. The clinical variables assessed were age, gender, diabetes, hypertension, hypercho- lesterolemia, current smoking status, Canadian Cardiovascular Society angina class, and prior myocardial infarction. Follow-up. Follow-up data were provided by the individual clinical sites after patient and/or physician contact by telephone or mail and supplemented by review of hospital records when necessary. Follow-up at each site was performed by a cardiovascular research nurse or physician.
Definitions of Outcomes
Procedural success. Procedural success was defined as a reduction in diameter stenosis in one or more stenoses to less than 50% stenosis associated with clinical improvement and no major ischemic complications (death, bypass surgery, or myocardial infarction).
Intermediate-term event-free survival. Intermediateterm event-free survival was defined as freedom from death, bypass surgery, and myocardial infarction at the time of latest follow-up.
Statistical Analysis
All data were entered into the MAPS data bank at the data coordinating center. Data are expressed as mean+ 1 SD unless otherwise indicated. Cox proportional hazards regression analyses were used to determine the clinical and angiographic correlates of event-free survival, freedom from death, freedom from bypass surgery, and freedom from myocardial infarction. For each of these analyses, patients were censored at the time of their death from obvious noncardiac causes. If the cause of death could not be determined, it was considered to be cardiac in origin. For each of these analyses, clinical and angiographic variables were prospectively divided into those that were simple, intermediate, or complex to determine. Preliminary Cox analyses were performed within each of these three groups of variables. A final sequential Cox analysis was then performed, entering first the significant variables from the simple group and then the variables from the intermediate and complex variable groups, but only if they provided significant additional information. This method of analysis was chosen to evaluate the usefulness of the variables in the clinical setting. The variables defined as simple were age, Canadian Cardiovascular Society angina class, diabetes, gender, hypercholesterolemia, hypertension, number of diseased vessels, number of stenoses of 50% or greater, prior myocardial infarction, proximal left anterior descending coronary artery stenosis of 50% or greater, and smoking. The variables defined as intermediate in complexity were the primary target stenosis risk score, the sum of all stenosis risk scores, and the sum of all stenosis simplified riskterritory scores. The variables defined as complex were the primary target stenosis risk-territory score, the sum of all stenosis risk-territory scores, the primary target stenosis risk-territory-contractility score, and the sum of all stenosis risk-territory-contractility scores. Analyses were performed using SAS software from SAS Institute Inc., Cary, N.C. Results 
Patient Characteristics
Cineangiograms from 350 patients (1,100 stenoses) were analyzed. Characteristics of the study patients are enumerated in Table 2 . Of importance, 72% of the patients had severe angina (Canadian Cardiovascular Society class III or IV), the majority of patients (68%) had two-vessel coronary disease, left ventricular function was usually well preserved (ejection fraction, 58+12%), and 1.9+1.0 stenoses per patient were dilated. The stenoses dilated were of mixed complexity, with 29% having characteristics suggestive of expected high success and low complication rates (ACC/AHA type A), 61% having characteristics of expected moderate success and complication rates (ACC/AHA type B), and 10% having characteristics suggestive of expected low success and high complication rates (ACC/AHA type C).
Overall Clinical Outcome
Two hundred ninety-nine of 350 patients (85.4%) had at least one stenosis successfully dilated, no complications, and an improvement in functional status. Major procedural complications occurred in 30 of 350 patients (8.6%) (death, four of 350, 1.1%; nonfatal emergency bypass surgery, 20 of 350, 5.7%; nonfatal myocardial infarction without bypass surgery, six of 350, 1.7%).
Mean duration of follow-up for patients with eventfree survival was 22±10 months. Three patients (0.9%) were lost to follow-up. The event-free survival by life-table analysis was 72.3% at 24 months. The incidence rates of death, bypass surgery, and myocardial infarction without bypass surgery were 4.5%, 17.8%, and 3.8%, respectively (see Figure 2 ). An Figure 3 and Figure 4 and in tabular form in Table 4 Figure 4 and in tabular form in |~~~~~~~~~'
Class C Correlates of Bypass Surgery The correlates of bypass surgery are shown graphically in Figure 4 and in tabular form in Table 6 Discussion Despite increased use of coronary angioplasty to treat patients with multivessel coronary disease and several studies reporting a 64-91% event-free (death, bypass surgery, or myocardial infarction) 7-37-month survival in carefully selected patients,457,1013 no study has addressed the issue of defining criteria by which to assess the likelihood of intermediate-or long-term event-free survival in a given patient.
The present study, in which 350 consecutive and carefully characterized patients with multivessel disease undergoing coronary angioplasty were followed for nearly 2 years, was designed to identify the predictors of and define the nature of late outcome after PTCA in this patient population.
Four conclusions are noteworthy. First, of the 27.6% of patients experiencing a major adverse outcome within 2 years of the index angioplasty, approximately two thirds had bypass surgery and survived without myocardial infarction, whereas the rates of death and myocardial infarction within 2 years were low-4.5% and 3.8%, respectively.
Second, there was a wide patient-to-patient variation in event-free survival, overall survival, and freedom from bypass surgery and myocardial infarction that were highly correlated with simple and readily obtainable clinical and angiographic characteristics (see Figures 3 and 4) . Event-free survival was independently predicted by three simple (Canadian Cardiovascular Society angina class, diabetes, and presence of a significant stenosis in a proximal left anterior descending coronary artery) and one intermediately complex (sum of all stenosis simplified risk territory scores) variables. Patients with silent or class I angina had an 88% event-free 2-year survival compared with 78% for patients with class II or III angina and 67% for patients with angina at rest (p=0.04). This difference first became apparent at the time of the initial procedure and continued to increase throughout follow-up. It is probably explained in part by the higher incidence of ischemic procedural complications reported in patients with unstable ischemic syndromes,14,15 by the higher frequency of restenosis in patients with unstable angina, 16 Third, highly complex analyses evaluating stenosis morphology, topography, and regional left ventricular contractility in the area subserved by the stenosis were not required to assess outcome. Although the sum of all stenosis risk-territory scores was the best overall predictor of event-free survival, it added no independent prognostic value once the impact of simpler variables was considered. Two variables of intermediate complexity added independent prognostic information and should be considered in clinical decision making. The sum of all stenosis simplified risk-territory scores-the additive effect of the stenosis risk score (class A, one point; class Bi, two points; class B2, three points; class C, four points) multiplied by 2 for proximal and mid artery stenoses and by 1 for distal or branch stenoses for all 50% or greater stenoses (see Figure 2) -was a significant correlate of event-free survival even after all simpler variables were considered. Only 54% of patients with scores of 16 Fourth, the often-used descriptor of coronary artery disease severity-"number of diseased vessels"-although a significant univariate predictor of outcome, was not as important as angina class, diabetes, and proximal left anterior descending coronary artery disease and did not enter as a significant independent correlate of outcome in the Cox model.
Implications
Ideal multivessel disease patients for coronary angioplasty. Based on the findings of the present study, the patient without diabetes, proximal left anterior descending coronary artery stenoses, or rest pain; with a sum of stenosis simplified risk-territory score of 15 or less; and in need of revascularization would be considered ideal for referral for PTCA. On the basis of the findings of the present study, their expected 2-year event-free survival rate would be 87%, with an overall survival at 2 years of 100% (n=70).
Poor candidates for coronary angioplasty. Patients with two or more of these risk factors, particularly if their left ventricular ejection fraction was less than 40%, should be referred for PTCA only under unusual circumstances because of an expected 2-year event-free survival rate of less than 50% and a mortality rate of more than 25%. Patients with only one risk factor should be considered individually. However, given the adverse impact on both eventfree and overall survival rates of proximal left anterior descending coronary artery stenoses and the excellent expected outcome after internal mammary artery grafting in that setting,24 the finding of important stenoses in that coronary segment in patients with multivessel disease should be considered a relative contraindication to PTCA. Limitations. In considering the results, certain limitations of the present study should be kept in mind. First, the majority of these patients had two-vessel coronary disease and well-preserved left ventricular function and do not reflect the distribution of coronary artery involvement and functional impairment of all patients in multivessel coronary disease. 25 The importance of left ventricular function and the extent of the disease in the determination of late outcome defined herein suggest that long-term rates of adverse events would be higher than those reported if the study population was more representative of all patients with multivessel disease. Second, to a certain extent, assessment of coronary artery morphology is subjective,26 and the use of these data to assist in clinical decision making requires strict attention to the details of the definitions used. Third, this is not a randomized comparison of treatments, and definitive statements regarding the efficacy of coronary angioplasty versus bypass surgery or other forms of therapy must await carefully randomized comparisons of prospectively defined subgroups of patients in this heterogeneous population. Fourth, improved results with angioplasty may be seen with lower-profile balloons or the concomitant use of intracoronary stents,27 laser balloon angioplasty,28 atherectomy,29 and other evolving adjunctive technologies. Finally, this assessment does not include the possible impact of completeness of revascularization on outcome because complete revascularization is dependent on the procedural result and therefore cannot be determined with certainty before beginning the procedure.
Conclusions
The considerable patient-to-patient variation in late outcome after coronary angioplasty for patients with multivessel coronary disease appears to be highly correlated with readily identifiable clinical and anatomic risk factors. Identification of such risk factors should improve clinical decision making and provide a framework on which to base prospective subgroup evaluations in randomized trials comparing standard coronary angioplasty with other treatment modalities in patients with multivessel coronary disease.
